Survodutide vs cagrilintide: how these investigational obesity drugs differ in mechanism, trial results, and side effects.
Survodutide and cagrilintide are two investigational, once-weekly injectable drugs being studied for obesity, but they work in completely different ways. Survodutide is a dual GLP-1 and glucagon receptor agonist, while cagrilintide is a long-acting amylin analog. Neither is FDA-approved for weight loss, and the two have never been compared head-to-head in a clinical trial, so any comparison today rests on separate studies.
What Is Survodutide?
Survodutide, also called BI 456906, is being developed by Boehringer Ingelheim and Zealand Pharma. It is a dual agonist: one molecule switches on two gut-hormone receptors at once.
- GLP-1 receptors — the target of semaglutide, tirzepatide, and liraglutide, which curb appetite and slow stomach emptying.
- Glucagon receptors — a target that may raise energy expenditure and help clear fat from the liver.
The glucagon component is what sets survodutide apart from pure GLP-1 drugs. In a Phase 2 obesity trial, adults without type 2 diabetes lost up to roughly 15% of their body weight after about 46 weeks. A separate Phase 2 trial in MASH showed substantial liver-fat reduction, and the FDA granted survodutide Breakthrough Therapy designation for MASH in 2024.
Survodutide is now in Phase 3 testing for obesity and MASH. Because dual and triple agonists are moving quickly through development, researchers often weigh survodutide vs retatrutide when comparing mechanisms and early results.
What Is Cagrilintide?
Cagrilintide is a long-acting version of amylin, a hormone the pancreas releases alongside insulin after a meal. Amylin slows gastric emptying and signals fullness to the brain, which is why amylin-based drugs are studied for weight loss.
Novo Nordisk designed cagrilintide for once-weekly injection, giving it a far longer half-life than pramlintide, an older amylin drug approved for diabetes. As a standalone treatment, cagrilintide produced up to 10.8% weight loss at 26 weeks in a Phase 2 trial of adults with obesity who did not have diabetes.
Most of the drug's development, however, centers on combination therapy. CagriSema combines cagrilintide with semaglutide 2.4 mg. In the Phase 3 REDEFINE 1 trial, CagriSema produced roughly 20% to 23% weight loss at 68 weeks, depending on which analysis is used.
Amylin-based obesity drugs are a new class, so many early reviews focus on a single pairing such as petrelintide vs cagrilintide. Survodutide is not the only dual GLP-1/glucagon agonist in development either, which is why loosely related pairings like mazdutide vs cagrilintide also appear in pipeline roundups.
Survodutide vs Cagrilintide at a Glance
| Feature | Survodutide | Cagrilintide |
|---|---|---|
| Drug class | Dual GLP-1/glucagon receptor agonist | Long-acting amylin analog |
| Developers | Boehringer Ingelheim and Zealand Pharma | Novo Nordisk |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Monotherapy weight loss | Up to about 15% at roughly 46 weeks (Phase 2, no type 2 diabetes) | Up to 10.8% at 26 weeks (Phase 2, no diabetes) |
| Main combination studied | None; developed as a standalone drug | CagriSema, with semaglutide 2.4 mg |
| Development stage | Phase 3 for obesity and MASH | Phase 3; submitted for review as part of CagriSema |
| Common side effects | Nausea, vomiting, diarrhea, constipation, possible heart-rate increase | Nausea, vomiting, diarrhea, constipation, injection-site reactions |
| FDA approval for weight loss | None | None as a standalone drug |
How Do the Weight-Loss Results Compare?
No trial has pitted survodutide against cagrilintide, so the numbers below come from different studies with different doses, populations, and treatment durations.
- Survodutide Phase 2: up to about 15% weight loss at roughly 46 weeks as a single agent, in adults without type 2 diabetes.
- Cagrilintide Phase 2: up to 10.8% weight loss at 26 weeks as a single agent, in adults without diabetes.
- CagriSema Phase 3: roughly 20% to 23% at 68 weeks when cagrilintide is paired with semaglutide 2.4 mg.
A drug tested for 46 weeks cannot be fairly compared with one tested for 26 weeks, and results in people with type 2 diabetes are typically lower than results in people without it. That is why cross-trial comparisons of weight-loss percentages should be treated as rough context, not proof that one drug is stronger.
Cagrilintide also has fewer standalone data points than survodutide, because Novo Nordisk has pushed it mainly as a combination partner. Readers comparing it with other incretin drugs often start with cagrilintide vs tirzepatide, which contrasts an amylin analog with a dual GLP-1/GIP agonist.
The same framing applies to cagrilintide vs retatrutide, where a single amylin analog is measured against a triple agonist. Different mechanisms produce different average weight loss, so the drug class matters as much as the headline percentage.
Side Effects and Safety Considerations
Both drugs belong to the same broad family of gut-hormone therapies, and both commonly cause digestive side effects.
- Nausea, vomiting, diarrhea, and constipation are the most frequent complaints for each drug.
- Cagrilintide trials also report injection-site reactions.
- Survodutide's glucagon activity has been linked to a modest rise in heart rate, which researchers continue to monitor.
Class-wide safety questions for this drug family include pancreatitis, gallbladder disease, and gastroparesis. Long-term safety data for both survodutide and cagrilintide remain limited because neither drug has completed a full Phase 3 program.
People with a history of pancreatitis, gallbladder disease, or slowed stomach emptying should discuss the risks with a healthcare professional before considering any investigational or approved GLP-1-based medication.
Which One Is Better?
There is no evidence-based winner between survodutide and cagrilintide, because no head-to-head trial exists. Survodutide is being developed as a single drug that carries its own weight-loss effect, while cagrilintide's most impressive results come from pairing it with semaglutide.
Both remain investigational, which means neither can be prescribed for weight loss in the United States outside of a clinical trial. Availability will depend on Phase 3 results and regulatory review.
If both eventually reach the market, the choice will likely come down to how much weight loss a patient needs, which side effects they can tolerate, and whether a combination product outperforms a single-agent option.
Frequently Asked Questions
Is survodutide or cagrilintide FDA-approved?
Neither drug is FDA-approved for weight loss. Cagrilintide is not sold as a standalone product, though its combination with semaglutide (CagriSema) has been submitted for regulatory review. Survodutide is still in Phase 3 trials for obesity and MASH.
Which causes more weight loss, survodutide or cagrilintide?
In separate trials, survodutide produced up to about 15% weight loss at roughly 46 weeks, while cagrilintide alone produced up to 10.8% at 26 weeks. Those figures cannot be compared directly because the studies used different treatment durations, doses, and patient populations.
Can survodutide and cagrilintide be taken together?
No trial has tested survodutide and cagrilintide in combination, so there is no safety or dosing data for that pairing. Both drugs affect appetite and gut motility, so overlapping side effects would be a real concern. Using them together outside a supervised clinical trial would be unsafe.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.